TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00859781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-J591
Description: 177Lu-J591 70 mCi/m2 on day 29 (+/- 2 days) of treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: Ketoconazole at a dose of 400 mg (two 200 mg tabs) to be taken orally (preferably on an empty stomach) three times per day (total daily dose of 1200 mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketoconazole
Description: Ketoconazole at a dose of 400 mg (two 200 mg tabs) to be taken orally (preferably on an empty stomach) three times per day (total daily dose of 1200 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Hydrocortisone at a dose of 20 mg orally each morning, 10 mg orally each evening (total daily dose of 30 mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydrocortisone
Description: Hydrocortisone at a dose of 20 mg orally each morning, 10 mg orally each evening (total daily dose of 30 mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 111In-J591
Description: 111In-J591 at a dose of 5 mCi on day 29 (+/- 2 days) of treatment
Study: NCT01716533

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sampling
Description: Blood sampling will be done at Day 0, at Day 14, at recurrence (if applicable) and at end of follow-up.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sampling
Description: Blood sampling will be done at Day 0, at Day 14, at recurrence (if applicable) and at end of follow-up.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sampling
Description: Blood sampling will be done at Day 0, at Day 14, at recurrence (if applicable) and at end of follow-up.
Study: NCT00682617

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Waitlist, delayed intervention
Description: Due to limited space in exercise intervention classes, subjects may be placed on a waitlist for 3 months. When an opening becomes available, the subject will begin the exercise program identical to that of Group 2
Study: NCT01716533

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sampling
Description: Blood sampling will be done at Day 0, at Day 14, at recurrence (if applicable) and at end of follow-up.
Study: NCT01679197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metreleptin
Study: NCT01716533

Intervention type: OTHER
Group type: OTHER
Intervention: Stool sample collection
Description: Stool samples will be collected around Day 0, around Day 14 and at recurrence (if applicable).
Study: NCT00990847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Procaterol, Salbultamol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Procaterol, Salbultamol
Study: NCT04663438

Intervention type: DRUG
Intervention: Chemotherapy Drugs, Cancer
Description: Other chemotherapy:Irinotecan;topotecan;Enrotinib;Bevacil

Intervention type: DRUG
Intervention: Chemotherapy Drugs, Cancer
Description: Other chemotherapy:Irinotecan;topotecan;Enrotinib;Bevacil
Study: NCT04059549

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PartnerCHESS
Description: Patients randomized to the PartnerCHESS group will receive all A-CHESS services plus the following services from ABCT:~Urge discussion. Daily EMAs will track preconditions for relapse (urges), review urge reduction options on PartnerCHESS, and encourage discussions between partners on the causes of and ways to reduce urges.~Homework checklist. Tracks which interventions the couple is using/practicing, along with resources to help.~Relapse plan. Monitoring and reminders of steps planned for relapse prevention. Reminders. Reminders to notice something positive in partner, of reasons to stay sober, to take meds, etc.~Trigger identification and removal. During set-up, patient and partner enter triggers. PartnerCHESS will quiz couples on upcoming trigger events and remind them of ways to address each.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PartnerCHESS
Description: Patients randomized to the PartnerCHESS group will receive all A-CHESS services plus the following services from ABCT:~Urge discussion. Daily EMAs will track preconditions for relapse (urges), review urge reduction options on PartnerCHESS, and encourage discussions between partners on the causes of and ways to reduce urges.~Homework checklist. Tracks which interventions the couple is using/practicing, along with resources to help.~Relapse plan. Monitoring and reminders of steps planned for relapse prevention. Reminders. Reminders to notice something positive in partner, of reasons to stay sober, to take meds, etc.~Trigger identification and removal. During set-up, patient and partner enter triggers. PartnerCHESS will quiz couples on upcoming trigger events and remind them of ways to address each.
Study: NCT01716533

Intervention type: OTHER
Group type: OTHER
Intervention: Stool sample collection
Description: Stool samples will be collected around Day 0, around Day 14 and at recurrence (if applicable).

Intervention type: OTHER
Group type: OTHER
Intervention: Stool sample collection
Description: Stool samples will be collected around Day 0, around Day 14 and at recurrence (if applicable).
Study: NCT04059549

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: A-CHESS
Description: A-CHESS control group
Study: NCT03168256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CF101 2mg
Description: CF101 tablets, 2mg BID for 16 weeks
Study: NCT03168256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CF101 3mg
Description: CF101 tablets, 3mg BID for 16 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apremilast 30mg
Description: Apremilast tablets, 30mg BID for 16 weeks
Study: NCT02914249

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orange juice (500 mL/d)
Description: Nutritionists prescribed a low-calorie diet that was estimated from total energy expenditure (TEE) for each individual minus 500 kcal per day (30% TEE). Both groups had the same diet plan based on individual weight. The dietary plan was composed of six meals/day: breakfast (fat-free milk and coffee; whole-grain bread with margarine, and an apple); snack 1 (250 mL OJ / banana and free-fat yogurt); lunch (brown rice, beans, grilled lean meat, salad, cooked vegetables); snack 2 (250 mL OJ / free-fat yogurt with oatmeal); dinner (brown rice, beans, grilled lean meat, cooked vegetables and salad); and snack 3 (salty crackers or oat cookies, tea without sugar). Body composition measurements were collected (monthly); blood samples and dietary questionnaires (every two weeks).
Study: NCT03168256

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo tablets, BID for 16 weeks
Study: NCT02989298

Intervention type: OTHER
Intervention: No intervention
Description: Registration of all PD patients in the First Affiliated Hospital of Sun Yat-sen University and other hospitals，which have signed the contract in China.
Study: NCT02107079

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: swallowing 1 piece, collecting saliva afterwards

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: swallowing 1 piece, collecting saliva afterwards

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: swallowing 1 piece, collecting saliva afterwards
Study: NCT01872845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin 40mg
Description: Pravastatin 40mg PO daily for 1year from the day of BES implantation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Rosuvastatin 20mg PO daily for 1year from the day of BES implantation
Study: NCT03918941

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carey
Description: mobile application

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Carey
Description: mobile application
Study: NCT04079894

Intervention type: OTHER
Intervention: Standard Movement Protocol
Description: Participant walking, cycling and sitting according to a pre-specified protocol.

Intervention type: DEVICE
Intervention: Accerelerometer Monitoring
Description: 7 days of accelerometer monitoring in participants home-environment.

Intervention type: DEVICE
Intervention: Accerelerometer Monitoring
Description: 7 days of accelerometer monitoring in participants home-environment.
Study: NCT03918941

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional information
Description: leaflet, internet link and oral information

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional information
Description: leaflet, internet link and oral information
Study: NCT04432519

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate dental implant placement
Description: Dental implant insertion in the same surgical stage of the tooth extraction, consisting in implant placement in the fresh socket.
Study: NCT04079894

Intervention type: DEVICE
Intervention: Accerelerometer Monitoring
Description: 7 days of accelerometer monitoring in participants home-environment.
Study: NCT03673241

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Guardian System
Description: The Study arm will have the Guardian system applied to their bed and recovery chair with the intent for the patient to have the inflatable surface utilized underneath them .
Study: NCT04432519

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate dental implant placement
Description: Dental implant insertion in the same surgical stage of the tooth extraction, consisting in implant placement in the fresh socket.
Study: NCT03913702

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac Tromethamine
Description: 2ml of injectable Ketorolac (30mg/ml) will be mixed with 8ml of lidocaine HCL (1% without epinephrine) and delivered into the subacromial joint (total of 60mg of active substance in 10ml).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone Acetate
Description: 1ml of injectable Methylprednisolone (80mg/ml) will be mixed with 9ml of lidocaine HCL (1% without epinephrine) and delivered into the subacromial joint (total of 80mg of active substance in 10ml)
Study: NCT04574635

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study: NCT02616237

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Description: East-meets-West Lifestyle Intervention elements include nutrition and exercise from the Western perspective, food therapy and acupressure from the Traditional Chinese Medicine perspective, self-monitoring, and motivational videos of successful stories from working colleagues. The group participants in the Facebook are encouraged to post their health behaviors and questions, self-monitor, pledge for weight loss, seek social support and interact with health partners and other participants.
Study: NCT00000251

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 30% N2O

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 30% N2O

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 30% N2O

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.2% isoflurane

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.2% isoflurane

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.4% isoflurane

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.4% isoflurane

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 100% oxygen
Description: Placebo
Study: NCT02863380

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Functional magnetic resonance imaging used to individualize rTMS protocol
Description: Procedure consisting in personalizing the rTMS targets and stimulation pattern based on functional magnetic resonance imaging

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Functional magnetic resonance imaging used to individualize rTMS protocol
Description: Procedure consisting in personalizing the rTMS targets and stimulation pattern based on functional magnetic resonance imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Functional magnetic resonance imaging used to individualize rTMS protocol
Description: Procedure consisting in personalizing the rTMS targets and stimulation pattern based on functional magnetic resonance imaging

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Individualized rTMS (transcranial magnetic stimulation)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Classical rTMS (transcranial magnetic stimulation)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Classical tDCS (transcranial direct current stimulation)
Study: NCT02842424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril
Description: Ramipril therapy will start at 2.5mg/day for 1 week. Then 5mg/day for 1 week and will be increased to 10mg/day by the third week. The patients will stay on Ramipril 10mg/day for 22 weeks.
Study: NCT02079155

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: robot-assisted laparoscopic surgery
Description: Undergo RALP

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: robot-assisted laparoscopic surgery
Description: Undergo R-LESS RP

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study: NCT03244579

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Adjusting the quantity and quality of food intake to improve glycemic control, maternal and newborn health outcomes of women with gestational diabetes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Adjusting the quantity and quality of food intake to improve glycemic control, maternal and newborn health outcomes of women with gestational diabetes.
Study: NCT03983889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam is used as a common medication for sedation in all groups.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam is used as a common medication for sedation in all groups.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam is used as a common medication for sedation in all groups.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam is used as a common medication for sedation in all groups.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl is another opioid drug used for analgesia to prevent bronchoscopy induced cough.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl is another opioid drug used for analgesia to prevent bronchoscopy induced cough.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine is used for sedation in bronchoscopy with less impact on respiration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine is used for sedation in bronchoscopy with less impact on respiration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Remifentanil is used for analgesia to prevent bronchoscopy induced cough.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Remifentanil is used for analgesia to prevent bronchoscopy induced cough.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol is used for sedation with high efficacy but more side effect on respiration than dexmedetomidine.
Study: NCT05603520

Intervention type: OTHER
Intervention: Collection of Clinical Data
Description: prospectively and systematically collection of clinical research data from apparently healthy volunteers and patients with aortic stenosis and aneurysms

Intervention type: OTHER
Intervention: Collection of Clinical Data
Description: prospectively and systematically collection of clinical research data from apparently healthy volunteers and patients with aortic stenosis and aneurysms

Intervention type: OTHER
Intervention: Collection of Clinical Data
Description: prospectively and systematically collection of clinical research data from apparently healthy volunteers and patients with aortic stenosis and aneurysms
Study: NCT01907282

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Focused Treatment
Description: Treatment for family that focuses on skills for coping with subthreshold positive and negative symptoms and improving family communication and problem-solving

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Care
Description: This 3-session psychoeducational treatment assists individuals and families in coping with early warning signs of psychotic episodes.
Study: NCT01731782

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline placebo (for bupivacaine)
Description: Normal saline to mimic bupivacaine
Study: NCT02298725

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DGA Diet Plan
Description: A nutrient-adequate, balanced diet providing energy to maintain body weight, and macronutrient composition falling within the acceptable range, as recommended by the Institute of Medicine. The foods provided in this diet will be closely aligned with food group recommendations set in the 2010 Dietary Guidelines for Americans.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NHANES Diet Plan
Description: A nutrient-adequate, balanced diet providing energy to maintain body weight, and macronutrient composition falling within the acceptable range, as recommended by the Institute of Medicine. The foods provided in this diet will be closely aligned with the NHANES What we eat in America report.
Study: NCT02418091

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth
Description: Using Telehealth to slow progression of diabetic kidney disease automated population program identifies patients and engages them to optimize DKD medication adherence and health behaviors using 2-way communication via patient-selected technology (mobile/web-based applications, text messaging, interactive voice response, or e-mail) backed by case management via the phone for suboptimal control or health status. The STOP-DKDAutomated Population Program will deliver a tailored, multi-factorial intervention to address medication self-management and modify multiple risk factors simultaneously through a combination of patient self-monitoring, behavioral therapies and education that optimize adherence and self-efficacy.
Study: NCT02499887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: beclamethasone dipropionate
Description: Inhaler
Study: NCT04136639

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Miswak
Description: sticks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Grape Seed Extract Mouthwash
Description: Mouthwash

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: fluoride
Description: mouthwash
Study: NCT02499887

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: albuterol
Description: Inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albuterol
Description: Inhaler
Study: NCT03751150

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise program
Description: The runners will be asked to perform the training program twice a week. The intervention consist of muscle control and foam rolling exercises for the lower extremities.
Study: NCT04668391

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided anterior quadratus lumborum block at the lateral supra-arcuate ligament
Description: Bilateral single-injection 20 ml 0.56% ropivacaine. Intravenous analgesia was started postoperatively and consisted of 1ug/ml sufentanil，2 ml/h with a 5-minute lockout period, a limited 12 ml/h dose.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic epidural analgesia
Description: A thoracic epidural at the level of T7-10. Epidural infusion was started postoperatively and consisted of sufentanil (0.6ug/mL) and ropivacaine（0.2%） at 3ml/h.
Study: NCT02499887

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Oral corticosteroid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Oral corticosteroid
Study: NCT06034626

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intense pulsed light
Description: Each MGD patient underwent three treatment sessions at three-week intervals and three follow-up examinations over the course of treatment.
Study: NCT01436838

Intervention type: DRUG
Intervention: Interferon beta-1b (Betaseron, BAY86-5046)
Description: All patients will be prescribed with Betaseron and be instructed on treatment by their phisicians
Study: NCT06554262

Intervention type: OTHER
Intervention: No intervention
Description: No intervention was involved in this study
Study: NCT00246012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intetumumab
Description: Intetumumab will be administered at the dose of 3 milligram per kilogram (mg/kg) as intravenous infusion (a fluid or a medicine delivered into a vein by way of a needle) over a period of 2 hours (hr) (± 15 minutes) once every 3 weeks until the occurrence of dose limiting toxicities (DLTs). In Phase 2, intetumumab (5 mg/kg or 10 mg/kg) will be administered for 8 cycles until no evidence of disease progression or unacceptable toxicity. If a participant responds to therapy with stable disease (SD) or better, the participant will be eligible to receive up to 8 cycles of extended administrations.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intetumumab
Description: Intetumumab will be administered at the dose of 3 milligram per kilogram (mg/kg) as intravenous infusion (a fluid or a medicine delivered into a vein by way of a needle) over a period of 2 hours (hr) (± 15 minutes) once every 3 weeks until the occurrence of dose limiting toxicities (DLTs). In Phase 2, intetumumab (5 mg/kg or 10 mg/kg) will be administered for 8 cycles until no evidence of disease progression or unacceptable toxicity. If a participant responds to therapy with stable disease (SD) or better, the participant will be eligible to receive up to 8 cycles of extended administrations.